7 results on '"Cortes, Raquel"'
Search Results
2. Optimization of small RNA library preparation protocol from human urinary exosomes
- Author
-
Olivares, Dolores, Perez-Hernandez, Javier, Perez-Gil, Daniel, Chaves, Felipe J., Redon, Josep, and Cortes, Raquel
- Published
- 2020
- Full Text
- View/download PDF
3. Mesenchymal Stem Cell-Derived Extracellular Vesicles as Non-Coding RNA Therapeutic Vehicles in Autoimmune Diseases.
- Author
-
Martinez-Arroyo, Olga, Ortega, Ana, Forner, Maria J., and Cortes, Raquel
- Subjects
NON-coding RNA ,EXTRACELLULAR vesicles ,AUTOIMMUNE diseases ,TYPE 1 diabetes ,REGENERATIVE braking ,SYSTEMIC lupus erythematosus - Abstract
Autoimmune diseases (ADs) are characterized by the activation of the immune system against self-antigens. More common in women than in men and with an early onset, their incidence is increasing worldwide, and this, combined with their chronic nature, is contributing to an enlarged medical and economic burden. Conventional immunosuppressive agents are designed to alleviate symptoms but do not constitute an effective therapy, highlighting a need to develop new alternatives. In this regard, mesenchymal stem cells (MSCs) have demonstrated powerful immunosuppressive and regenerative effects. MSC-derived extracellular vesicles (MSC-EVs) have shown some advantages, such as less immunogenicity, and are proposed as novel therapies for ADs. In this review, we summarize current perspectives on therapeutic options for ADs based on MSCs and MSC-EVs, focusing particularly on their mechanism of action exerted through their non-coding RNA (ncRNA) cargo. A complete state-of-the-art review was performed, centralized on some of the most severe ADs (rheumatoid arthritis, autoimmune type 1 diabetes mellitus, and systemic lupus erythematosus), giving evidence that a promising field is evolving to overcome the current knowledge and provide new therapeutic possibilities centered on MSC-EVs and their role as ncRNA delivery vehicles for AD gene therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Urinary- and Plasma-Derived Exosomes Reveal a Distinct MicroRNA Signature Associated With Albuminuria in Hypertension.
- Author
-
Perez-Hernandez, Javier, Riffo-Campos, Angela L., Ortega, Ana, Martinez-Arroyo, Olga, Perez-Gil, Daniel, Olivares, Dolores, Solaz, Elena, Martinez, Fernando, Martínez-Hervás, Sergio, Chaves, Felipe J., Redon, Josep, and Cortes, Raquel
- Abstract
Urinary albumin excretion (UAE) is a marker of cardiovascular risk and renal damage in hypertension. MicroRNAs (miRNAs) packaged into exosomes function as paracrine effectors in cell communication and the kidney is not exempt. This study aimed to state an exosomal miRNA profile/signature associated to hypertension with increased UAE and the impact of profibrotic TGF-β1 (transforming growth factor β1) on exosomes miRNA release. Therefore, exosomes samples from patients with hypertension with/without UAE were isolated and characterized. Three individual and unique small RNA libraries from each subject were prepared (total plasma, urinary, and plasma-derived exosomes) for next-generation sequencing profiling. Differentially expressed miRNAs were over-represented in Kyoto Encyclopedia of Genes and Genomes pathways, and selected miRNAs were validated by real-time quantitative polymerase chain reaction in a confirmation cohort. Thus, a signature of 29 dysregulated circulating miRNAs was identified in UAE hypertensive subjects, regulating 21 pathways. Moreover, changes in the levels of 4 exosomes-miRNAs were validated in a confirmation cohort and found associated with albuminuria. In particular miR-26a, major regulator of TGF-β signaling, was found downregulated in both type of exosomes when compared with healthy controls and to hypertension normoalbuminurics (P<0.01). Similarly, decreased miR-26a levels were found in podocyte-derived exosomes after TGF-β stress. Our results revealed an exosomes miRNA signature associated to albuminuria in hypertension. In particular, exosomes miR-26a seemed to play a key role in the regulation of TGF-β, a relevant effector in podocyte damage. These findings support the use of exosomes miRNAs as biomarkers of cardiovascular risk progression and therapeutic tools in early kidney damage. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Increased Urinary Exosomal MicroRNAs in Patients with Systemic Lupus Erythematosus.
- Author
-
Perez-Hernandez, Javier, Forner, Maria J., Pinto, Carolina, Chaves, Felipe J., Cortes, Raquel, and Redon, Josep
- Subjects
SYSTEMIC lupus erythematosus ,EXOSOMES ,MICRORNA ,BIOMARKERS ,BODY fluid analysis ,REVERSE transcriptase polymerase chain reaction ,PATIENTS - Abstract
There is increased interest in using microRNAs (miRNAs) as biomarkers in different diseases. Present in body fluids, it is controversial whether or not they are mainly enclosed in exosomes, thus we studied if urinary miRNAs are concentrated inside exosomes and if the presence of systemic lupus erythematosus with or without lupus nephritis modifies their distribution pattern. We quantified specific miRNAs in urine of patients with systemic lupus erythematosus (n = 38) and healthy controls (n = 12) by quantitative reverse-transcription PCR in cell-free urine, exosome-depleted supernatant and exosome pellet obtained by ultracentrifugation. In control group, miR-335* and miR-302d were consistently higher in exosomes than in exosome-depleted supernatant, and miR-200c and miR-146a were higher in cell-free fraction. In lupus patients, all urinary miRNAs tested were mainly in exosomes with lower levels outside them (p<0.05 and p<0.01, respectively). This pattern is especially relevant in patients with active lupus nephritis compared to the control group or to the SLE patients in absence of lupus nephritis, with miR-146a being the most augmented (100-fold change, p<0.001). Among the exosomal miRNAs tested, only the miR-146a discriminates the presence of active lupus nephritis. In conclusion, urinary miRNAs are contained primarily in exosomes in systemic lupus erythematosus, and the main increment was found in the presence of active lupus nephritis. These findings underscore the attractiveness of exosomal miRNAs in urine, a non-invasive method, as potential renal disease markers. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Urinary exosome miR-146a is a potential marker of albuminuria in essential hypertension.
- Author
-
Perez-Hernandez, Javier, Olivares, Dolores, Forner, Maria J., Ortega, Ana, Solaz, Elena, Martinez, Fernando, Chaves, Felipe J., Redon, Josep, and Cortes, Raquel
- Subjects
MICRORNA ,EXOSOMES ,ALBUMINURIA ,ESSENTIAL hypertension ,BIOMARKERS - Abstract
Background: There is increasing interest in using extracellular vesicle-derived microRNAs (miRNAs) as biomarkers in renal dysfunction and injury. Preliminary evidence indicates that miRNAs regulate the progression of glomerular disease. Indeed, exosomes from the renal system have provided novel evidence in the clinical setting of albuminuria. Thus, the aim of this study was to quantify the urinary miRNAs present in exosome and microvesicles (MVs), and to assess their association with the presence of increased urinary albumin excretion in essential hypertension.Methods: Exosomes were collected from urine specimens from a cohort of hypertensive patients with (n = 24) or without albuminuria (n = 28), and from 20 healthy volunteers as a control group. Urinary exosomes were phenotyped by Western blot, tunable resistive pulse sensing, and electronic microscopy. Expression of miR-146a and miR-335* was analysed by qRT-PCR and any associations between albuminuria and exosomal miRNAs were analysed.Results: Urinary miRNAs are highly enriched in exosome subpopulations compared to MVs, both in patients with or without increased albuminuria (p < 0.001), but not in the control group. High albuminuria was associated with 2.5-fold less miR-146a in exosomes (p = 0.017), whereas miR-146a levels in MV did not change. In addition, exosome miR-146a levels were inversely associated with albuminuria (r = 0.65, p < 0.0001), and discriminated the presence of urinary albumin excretion presence [area under the curve = 0.80, 95% confidence interval: 0.66-0.95; p = 0.0013].Conclusions: Our results indicate that miRNAs were enriched in the urinary exosome subpopulation in hypertensive patients and that low miR-146a expression in exosomes was associated with the presence of albuminuria. Thus, urinary exosome miR-146a may be a potentially useful tool for studying early renal injury in hypertension. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
7. High miR-126-3p levels associated with cardiovascular events in a general population.
- Author
-
Martinez-Arroyo, Olga, Ortega, Ana, Flores-Chova, Ana, Sanchez-Garcia, Belen, Garcia-Garcia, Ana B, Chaves, Felipe J, Martin-Escudero, Juan C, Forner, Maria Jose, Redon, Josep, and Cortes, Raquel
- Subjects
- *
NUCLEOTIDE sequencing , *MAJOR adverse cardiovascular events , *ENDOTHELIUM diseases , *PROPORTIONAL hazards models , *HYPERTENSION - Abstract
• A renewed interest exists in miRNAs as biomarkers in cardiovascular disease. • miR-126–3p is associated with albuminuria, a marker of endothelial dysfunction, in hypertension. • High miR-126–3p levels are associated with cardiovascular events in general population. Endothelial dysfunction is a forerunner of atherosclerosis, leading to cardiovascular disease, and albuminuria is a marker of endothelial dysfunction. Circulating levels of microRNAs are emerging as potential biomarkers for cardiovascular disease. Here we estimate the predictive value of a plasma microRNAs signature associated with albuminuria in the incidence of cardiovascular events. Plasma microRNAs quantified in hypertensive patients by next generation sequencing were validated in a cohort of patients and controls by real-time quantitative PCR. The microRNAs found to be associated with albuminuria were analysed for their prognostic value in predicting cardiovascular events incidence on a retrospective, population-based study (Hortega Study), using Cox proportional hazard models. A plasma microRNA profile was identified in the discovery cohort (n = 48) associated with albuminuria and three microRNAs (miR-126–3p, miR-1260b and miR-374a-5p) were confirmed in the validation cohort (n = 98). The microRNA signature discriminates urinary albumin excretion at baseline (n = 1025), and predicts the incidence of cardiovascular events and coronary heart disease and stroke in a general population retrospective study within a 14-year follow-up (n = 926). High miR-126–3p levels were associated with a shorter time free of both cardiovascular events (HR=1.48, (1.36–1.62), p < 0.0001), as well as coronary artery disease and stroke combined (HR=2.49, (2.19–2.83), p < 0.0001). An increased plasma microRNAs profile was identified in hypertensive patients with albuminuria. Increased miR-126–3p suggest it may serve as a prognostic marker for cardiovascular events in a long-term general population. Further studies will assess the potential role of miR-126–3p as a guide for the status of endothelial dysfunction. Circulating miR-126–3p as a prognostic marker of MACE and combined CAD and stroke in a long-term general population cohort. A signature of 4 miRNAs is associated with albuminuria in the discovery and validation cohorts of hypertensive patients and controls. in a general population cohort (Hortega testing cohort) followed during 14 years, increased levels of plasma circulating miR-126–3p are associated with the incidence of MACE (major adverse cardiovascular events) and combined CAD (coronary artery disease) and stroke. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.